Which country is gilitinib produced in? Manufacturer and drug source analysis

Gilteritinib is a new FLT3 inhibitor, originally developed and produced by Astellas Pharma Inc. Giritinib is one of Astellas' representative innovative drugs in the field of oncology. It was approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of relapsed or refractory acute myeloid leukemia (AML) patients carrying FLT3 mutations, especially for patients with FLT3-ITD and FLT3-TKD mutations. It has significant efficacy. As the first oral FLT3 single-target inhibitor approved for this indication in the United States, the advent of giritinib has filled the gap in the lack of target treatments after traditional chemotherapy. Its launch is an important milestone in the field of precision medicine in the field of hematological tumors.

After being approved by the FDAGiritinib subsequently received marketing authorization from the EU EMA, Japan PMDA and other countries and regions. Its global clinical applications are produced and distributed by Astellas. The quality control system strictly follows the ICH (International Conference on Harmonization of Technology for the Registration of Drugs for Human Use) standards to ensure the safety and consistency of its drugs. In China, the drug has not yet been fully commercialized, but it has been included in some clinical trials and introduction routes through specific channels, such as Hainan Boao Licensed Medical Pilot Zone and overseas drug direct channels, providing domestic patients in need with access opportunities. At the same time, giritinib has also been included in a number of local clinical studies in China, which may pave the way for future local launch.

With the increasing global emphasis on personalized targeted therapy, innovative targeted drugs like giritinib are accelerating their introduction in many countries and becoming an important part of the treatment landscape for acute myeloid leukemia. When using giritinib, it is necessary to conduct clear FLT3 gene mutation testing to accurately match the population suitable for treatment. At the same time, pay attention to its potential adverse reactions such as abnormal liver function and QT interval prolongation, and follow the doctor's instructions for regular monitoring to ensure the safety and maximum efficacy of treatment.

Reference materials:https://www.xospata.com/